ClinicalTrials.gg
Active, not recruitingNCT06279403Updated Oct 27, 2026

Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

A Phase 2 interventional study of Toripalimab and Cytoreductive Nephrectomy in Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy and Clear Cell Renal Cell Cancer (ccRCC), sponsored by RenJi Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by RenJi Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now Active, not recruitingFirst site in China+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing toripalimab in Carcinoma, Renal Cell — 8 open to participants now, 11 under way, 1 of them phase 3. toripalimab · Carcinoma, Renal Cell.

Enrollment
11th of 13
21 · median 40
Started
2024
the only one that year
Phase 2
11 of 13
6 open now
Primary completion
2026-06
later than 1 of 10 live
Registered
5th of 13
by date
Lead sponsor
2 of 13
RenJi Hospital

Among the 13 studies testing toripalimab in Carcinoma, Renal Cell, this one is the 11th largest by enrollment, is the only one that started in 2024, is one of 11 in phase 2, reaches primary completion later than 1 of the 10 other live ones, and was the 5th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

8 of the 13 studies testing toripalimab in Carcinoma, Renal Cell are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About toripalimab

toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing toripalimab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Study Objective: To determine the efficacy of upfront immune checkpoint inhibitors combined with deferred cytoreductive nephrectomy in treating metastatic renal cell carcinoma.

Primary Endpoint: Pathological Major Response (MPR), defined as the percentage of residual tumor ≦10% in the primary tumor after nephrectomy.

Study Design:

Population: Participants meeting the diagnostic criteria with biopsy-proven clear cell renal cell carcinoma. Clinical staging by CT or MRI demonstrating either any T, N1, M0 disease or any T, any N, M1 disease, together with at least one of the following: an IMDC score ≤3; or ≤5 metastatic lesions involving ≤3 organs.

Patient Grouping: Non-randomized.

Interventions: Eligible participants will receive upfront treatment with a combination of Axitinib and Toripalimab for 4 cycles. After 2 cycles of treatment, radiological assessment will be conducted using RECIST 1.1 criteria. If disease progression is observed, the clinical trial will be terminated, and second-line treatment will be initiated according to guidelines. If disease progression is not observed, treatment will continue for 2 additional cycles followed by repeat radiological assessment before undergoing surgery.

03

Conditions studied

  • Immune Checkpoint Inhibitors
  • Cytoreductive Nephrectomy
  • Clear Cell Renal Cell Cancer (ccRCC)
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Willingness to participate in the study and provision of written .

Male or female participants aged ≥18 years and \<80 years. confirmed clear cell renal cell carcinoma or renal cell carcinoma with a predominant clear cell component.

Clinical staging by CT or MRI demonstrating either any T, N1, M0 disease or any T, any N, M1 disease, together with at least one of the following: an IMDC score ≤3; or ≤5 lesions involving ≤3 organs.

A primary renal tumor, whether unilateral or bilateral, considered resectable. performance status of 0 or 1. No abnormalities in cardiac, bone marrow, hepatic, or renal function.

Willingness and ability to comply with study assessments and follow-up procedures.

Exclusion criteria

Exclusion Criteria:

Non-clear cell carcinoma. Severe liver or kidney dysfunction, or other severe diseases. Immune deficiency, organ transplantation, or diseases. Severe central nervous system diseases. Other malignant tumors within the past 5 years, except for cured basal cell carcinoma of the skin and cervical carcinoma in situ.

Unable to comply with regular follow-up visits due to psychological, social, family, or geographical reasons.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Experimental

    Experimental arm

    Drug: Toripalimab · Procedure: Cytoreductive Nephrectomy · Drug: Axitinib

Interventions

  • Preoperative Treatment with Toripalimab: Administer 240mg of Toripalimab via intravenous infusion every 3 weeks for a total of 4 cycles.

  • ProcedureCytoreductive Nephrectomy

    Radical Nephrectomy: Complete resection of the tumor and affected kidney within the renal fascia. Partial Nephrectomy: Complete resection of the tumor while preserving maximal kidney function. Lymph Node Dissection: For patients with evident enlargement of retroperitoneal lymph nodes preoperatively, perform lymph node dissection at the renal hilum, along the ipsilateral major vessels, and anterior to the ipsilateral major vessels. Lymph node dissection is not required for patients without evident enlargement of retroperitoneal lymph nodes preoperatively.

  • Preoperative Treatment with Axitinib: Administer 5mg of axitinib orally twice daily for a duration of 3 months.

06

What researchers measure

Primary outcomes

  1. Pathological Major Response (MPR)

    The percentage of residual tumor in the primary tumor after surgery, with MPR defined as ≦10% of residual tumor.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • Renji
    Shanghai, Pudong 200127, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jun 2026, 27 months.

Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's 27 months is below that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Mar 2026 → Jun 2026 and completion Mar 2029 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2024
First posted
Feb 28, 2024
StartActual
Mar 1, 2024
Primary completionActual
Jun 30, 2026was Mar 2026
CompletionEst.
Jun 30, 2028was Mar 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 27, 2026
Sites
1 site added — first site in China
Show site
  • Renji · Shanghai, China
Oct 27, 2026
Primary completion
Mar 1, 2026→Jun 30, 2026 (actual)
Oct 27, 2026
Study completion
Mar 1, 2029→Jun 30, 2028
Oct 27, 2026
Enrollment
20 (estimated)→21 (actual)
Oct 27, 2026
Eligibility
5 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedVoluntary consentWillingness to participate in thisthe study and signingprovision of anwritten informed consent form.
  • EditedMale or female participants aged ≥18 years and <80 years. Histologically diagnosed with clear cell carcinoma or predominantlyconfirmed clear cell renal cell carcinoma or renal cell carcinoma with a predominant clear cell component.
  • ChangedBefore Clinical stage determined by CT or MRI: anyTN1M0 or anyTN0M1; IMDC score ≤3, or ≤5 metastatic lesions involving ≤3 organs; and the primary tumor (unilateral or bilateral) is resectable.Now Clinical staging by CT or MRI demonstrating either any T, N1, M0 disease or any T, any N, M1 disease, together with at least one of the following: an IMDC score ≤3; or ≤5 metastatic lesions involving ≤3 organs.
  • EditedA primary renal tumor, whether unilateral or bilateral, considered resectable. ECOG performance status: of 0 or 1. No clinically significant abnormalities in cardiac, bone marrow, hepatic, or renal function abnormalities.
  • EditedA willingnessWillingness and ability to comply with testingstudy assessments and follow-up procedures.
Oct 27, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionPathological Major Response (MPR): how it is measured was reworded
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Active, not recruiting
    1 site added — first site in China
    Show site
    • Renji · Shanghai, China
    Primary completion Mar 1, 2026→Jun 30, 2026 (now actual)
    Study completion Mar 1, 2029→Jun 30, 2028
    Enrollment 20 (estimated)→21 (actual)
    Eligibility 5 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedVoluntary consentWillingness to participate in thisthe study and signingprovision of anwritten informed consent form.
    • EditedMale or female participants aged ≥18 years and <80 years. Histologically diagnosed with clear cell carcinoma or predominantlyconfirmed clear cell renal cell carcinoma or renal cell carcinoma with a predominant clear cell component.
    • ChangedBefore Clinical stage determined by CT or MRI: anyTN1M0 or anyTN0M1; IMDC score ≤3, or ≤5 metastatic lesions involving ≤3 organs; and the primary tumor (unilateral or bilateral) is resectable.Now Clinical staging by CT or MRI demonstrating either any T, N1, M0 disease or any T, any N, M1 disease, together with at least one of the following: an IMDC score ≤3; or ≤5 metastatic lesions involving ≤3 organs.
    • EditedA primary renal tumor, whether unilateral or bilateral, considered resectable. ECOG performance status: of 0 or 1. No clinically significant abnormalities in cardiac, bone marrow, hepatic, or renal function abnormalities.
    • EditedA willingnessWillingness and ability to comply with testingstudy assessments and follow-up procedures.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPathological Major Response (MPR): how it is measured was reworded
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06279403
Lead sponsor
RenJi Hospital
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Mar 1, 2024
Primary completion
Jun 30, 2026
Completion
Jun 30, 2028 (estimated)
Last update
Oct 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Toripalimab · Axitinib

Start the discussion